Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Updates in the Treatment of Early-stage HR+ Breast Cancer

January 11th 2023

Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.

The Evolution of the Breast Cancer Treatment Landscape

January 11th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.

Sacituzumab Govitecan vs Treatment of Physician’s Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients with HR+/HER2– Metastatic Breast Cancer

January 10th 2023

Hope Rugo, MD discusses key data updates on the TROPiCS-02 study on sacituzumab govitecan in patients with endocrine-resistant, HR+/HER2- advanced breast cancer that were recently presented at the 2022 San Antonio Breast Cancer Symposium.

Dr. Bartsch on the Real-World Evaluation of the ELEANOR Study in HR+/HER2-Overexpressed Breast Cancer

January 6th 2023

Rupert Bartsch, MD, discusses interim findings produced from the real-world use of neratinib in select patients with hormone receptor-positive, HER2-overexpressed breast cancer.

Breast Cancer Advances in 2022 Showcase a Shifting Landscape

January 6th 2023

Joseph A. Sparano, MD, highlights practice-changing clinical trials, novel therapies, the evolving treatment landscape, and unmet needs in the field of breast cancer.

Dr. Lustberg on the Real-World Use of Ovarian Suppression in HR+/HER2+ Breast Cancer

January 5th 2023

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.

Dr. Kruse on the Effect of Socioeconomic Disparities on Survival Outcomes in Breast Cancer

January 5th 2023

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022

January 5th 2023

Drs Lu, Neven, Jacot, Medford, and Spring highlight updates in the treatment of hormone receptor–positive breast cancer that were presented at the 2022 San Antonio Breast Cancer Symposium.

Dr. Meisel on Effect of the HER2-Low Classification Breast Cancer

January 4th 2023

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

January 2nd 2023

Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic breast cancer, the reasons some patients refuse to undergo surgery, and potential strategies to overcome those objections.

Black, Hispanic Women Increasingly Likely to Refuse Surgery for Early Breast Cancer

January 1st 2023

Incidence of surgery refusal has increased by nearly 50% among Black and Hispanic women with potentially curable, nonmetastatic breast cancer over the past decade, according to findings from an analysis of Surveillance, Epidemiology, and End Results Program data.

Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer

December 26th 2022

Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.

DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer

December 26th 2022

Patient history and disease characteristics did not affect outcomes for patients with metastatic HER2-low breast cancer who received fam-trastuzumab deruxtecan-nxki in the DESTINY-Breast04 study.

Understanding the Smoking Gun

December 24th 2022

For the past 3 decades, Carlos L. Arteaga, MD, has focused his research on drug-resistant breast cancers, seeking to identify the causes of resistance and proposing combination therapies to beat that resistance.

Dr. Tarantino on the Impact of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

December 23rd 2022

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03

December 22nd 2022

Sara A. Hurvitz, MD, reviews updated data comparing trastuzumab deruxtecan versus trastuzumab emtansine for the treatment of HER2+ metastatic breast cancer.

Dr. Chaudhary on the Correlation of PD-L2 Status and PFS Rates in ER+ Breast Cancer

December 21st 2022

Lubna N. Chaudhary, MD, discusses the correlation between PD-L2 status and progression-free survival rates in treatment-naïve estrogen receptor–positive breast cancer.

Dr. Gadi on the Investigation of AMUN-003 in TNBC

December 21st 2022

Vijayakrishna Gadi, MD, PhD, discusses the investigation of AMUN-003 in triple-negative breast cancer.

Fluorouracil Is Inappropriate for Optimal Adjuvant Chemotherapy in High-Risk Early Breast Cancer

December 21st 2022

Updated results from the phase 3 GIM 2 study confirm previous findings showing that fluorouracil should not be a part of adjuvant chemotherapy for patients with high-risk early breast cancer.

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer

December 20th 2022

Peter A. Kaufman, MD, reviews data in patients with HER2+ metastatic breast cancer treated with tucatinib-based therapy.